| Trial | control | p<0.05 | harm | NS |
|---|
| Bellandi (propafenone vs placebo), 2001 | vs placebo | Atrial fibrillation recurrence 0.65 [0.50; 0.85] | | all cause mortality NaN [NaN; NaN] Withdrawals due to adverse effects 2.71 [0.76; 9.69] Pro-arrhythmia NaN [NaN; NaN] |
| Dogan, 2004 | vs placebo | Atrial fibrillation recurrence 0.69 [0.49; 0.97] | | all cause mortality 0.00 [0.00; NaN] Withdrawals due to adverse effects 3.59 [0.41; 31.07] Pro-arrhythmia ∞ [NaN; ∞] |
| FAPIS, 1996 | vs placebo | | | all cause mortality NaN [NaN; NaN] Withdrawals due to adverse effects 1.18 [0.50; 2.78] Pro-arrhythmia 2.12 [0.20; 23.05] Atrial fibrillation recurrence 1.06 [0.70; 1.62] |
| Kochiadakis b (propafenone vs placebo), 2004 | vs placebo | Atrial fibrillation recurrence 0.58 [0.44; 0.78] | | all cause mortality NaN [NaN; NaN] Withdrawals due to adverse effects ∞ [NaN; ∞] Pro-arrhythmia ∞ [NaN; ∞] |
| RAFT, 2003 | vs placebo | Atrial fibrillation recurrence 0.71 [0.63; 0.79] | | all cause mortality NaN [NaN; NaN] Withdrawals due to adverse effects 1.29 [0.79; 2.11] Pro-arrhythmia NaN [NaN; NaN] |
| Reimold, 1993 | vs placebo | | | all cause mortality ∞ [NaN; ∞] Withdrawals due to adverse effects 1.50 [0.45; 4.99] Pro-arrhythmia 1.50 [0.58; 3.90] Atrial fibrillation recurrence 0.91 [0.69; 1.20] |
| Richiardi, 1992 | vs placebo | | Withdrawals due to adverse effects 2.39 [1.20; 4.77] | all cause mortality 0.00 [0.00; NaN] Pro-arrhythmia 1.04 [0.15; 7.24] Atrial fibrillation recurrence 1.12 [0.87; 1.44] |
| Stroobandt, 1997 | vs placebo | | | all cause mortality 0.00 [0.00; NaN] Withdrawals due to adverse effects 1.14 [0.25; 5.12] Pro-arrhythmia 0.49 [0.09; 2.75] Atrial fibrillation recurrence 0.71 [0.50; 1.01] |
| Trial | Treatments | Patients | Method |
|---|
| Bellandi (propafenone vs placebo), 2001 | Propafenone 900 mg/d/d after pharmacological or electrical cardioversion (n=102) vs. placebo (n=92) | patients with paroxysmal recurrent or persistent AF | double blind Parallel groups Sample size: 102/92 Primary endpoint: FU duration: 12 months |
| Dogan, 2004 | Propafenone 450 mg/d (n=58) vs. placebo (n=52) | AF of duration 3 hours to 3 months ??? | single Parallel groups Sample size: 58/52 Primary endpoint: FU duration: 15 months |
| FAPIS, 1996 | propafenone 520 mg/dt (n=97) vs. Flecainide 200 mg/d (n=103) | Paroxysmal recurrent AF with > 2 episodes in the last 4 months | open Parallel groups Sample size: 97/103 Primary endpoint: FU duration: 12 months |
| Kochiadakis b (propafenone vs placebo), 2004 | Propafenone 450 mg/d (n=86) vs. placebo (n=83) | Any documented symptomatic previous or persistent AF
| single Parallel groups Sample size: 86/83 Primary endpoint: FU duration: 24 months |
| RAFT, 2003 | Propafenone at various doses (450, 650, 850 mg/d) (n=397) vs. placebo. (n=126) | Previous symptomatic AF documented in the last year | double blind Parallel groups Sample size: 397/126 Primary endpoint: FU duration: 9 months |
| Reimold, 1993 | Propafenone 675 mg/d (n=50) vs. Sotalol 320 mg/d (n=50) | Any symptomatic AF or AFlx-xbitm | open Parallel groups Sample size: 50/50 Primary endpoint: FU duration: 12 months |
| Richiardi, 1992 | Propafenone 900 mg/d (n=98) vs. Quinidine 1 g/d mg/d (n=102) | Paroxysmal AF having > 3 episodes in the last 3 months | open Parallel groups Sample size: 98/102 Primary endpoint: FU duration: 12 months |
| Stroobandt, 1997 | Propafenone 450 mg/d (n=77) vs. placebo (n=25) | Recent-onset AF or persistent AF lasting > 2 weeks | double blind Parallel groups Sample size: 77/25 Primary endpoint: FU duration: 6 months |
